Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.47 |
| ▸ | MDM4 | O15151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.39 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24966154 | 0.89 | CASP3 (0.41) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL24966155 | 0.89 | CASP3 (0.41) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29709552 | 0.86 | CASP3 (0.43) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29696715 | 0.85 | CASP3 (0.48) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29696610 | 0.82 | CASP3 (0.48) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29696671 | 0.81 | CASP3 (0.51) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL24580372 | 0.79 | CASP3 (0.48) | CASP3MDM4TP53KMT2A | |
| SCHEMBL26605906 | 0.79 | CASP3 (0.48) | CASP3MDM4TP53KMT2A | |
| SCHEMBL29696651 | 0.79 | CASP3 (0.48) | CASP3MDM4TP53KMT2A | |
| SCHEMBL29709561 | 0.79 | CASP3 (0.70) | CASP3MDM4TP53KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-02 | — | — | US | disclosed |
| CN-114630835-B | Process for the preparation of peptide compounds comprising sterically bulky amino acids | 中外制药株式会社 | 2025-02-11 | — | — | CN | disclosed |
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-4056580-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-14 | — | — | EP | disclosed |
| CN-114630835-A | Process for the preparation of peptide compounds comprising sterically bulky amino acids | 中外制药株式会社 | 2022-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | DNPEP, VIP, NPEPPS | CASP3 1864/4885MDM4 3528/4885TP53 1753/4885 |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | DNPEP, VIP, NPEPPS | CASP3 1864/4885MDM4 3528/4885TP53 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.